Durvalumab ± tremelimumab + platinum-etoposide in firstline extensive-stage SCLC (ES-SCLC): 36-monthoverall survival from the Phase 3 CASPIAN study

Authors
Category Primary study
ConferenceOncology Research and Treatment
Year 2022
This article has no abstract
Epistemonikos ID: e5a1d901b0af14204493bcfa4d8ef8cc02fdd0e5
First added on: Apr 30, 2026